?Effect of Dronedarone on prevention of atrial fibrilatio
Not Applicable
- Conditions
- Atrial Fibrillation.Atrial fibrillation and flutter
- Registration Number
- IRCT201202011965N2
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Age over 20 years; the first time, On-pump CABG
Exclusion criteria: Previous history of AF / AFL; AV block grade 2 and above; Sinus bradycardia with heart rate below 60 bpm; Hemodynamic instability (SBP <100 mmHg); Use of class I or III antiarrhythmia drugs and the other drugs that increase the QT; Uncontrolled heart failure (NYHA class III or IV); Severe liver disease; Valve replacement surgery at the same time; Hypercalemia (K <3.5 mmol / L) or uncontrolled hypermagnesiumia; Severe renal insufficiency (GFR <10 ml / min); Pregnancy and lactation; Amiodarone injection during CABG
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of AF. Timepoint: 7 days after intervention. Method of measurement: ECG.;AF duration. Timepoint: 7 days after intervention. Method of measurement: ECG/ In minute.
- Secondary Outcome Measures
Name Time Method CRP level. Timepoint: Daily for7 days. Method of measurement: Blood sampling, mg/l.;ICU stay duration. Timepoint: since being admitted to the ICU. Method of measurement: clinical records of patient.;Hospital stay duration. Timepoint: since being admitted to the hospital. Method of measurement: clinical records of patient.;Mortality. Timepoint: since being admitted to the hospital. Method of measurement: clinical records of patient.;Drug side effects. Timepoint: until adverse drug reaction. Method of measurement: Examination and clinical records of patient.